Medvi is one of many telehealth brands selling GLP-1 weight management under a flat monthly price, and it competes with names like Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare. The honest short answer: whether Medvi is a better deal than the others depends almost entirely on one thing most reviews skip, which is whether you are buying compounded medication or a brand prescription. Those are different products, and comparing their prices as if they were the same is the mistake that runs through most Medvi reviews.
What are these brands actually selling?
The GLP-1 telehealth field splits into two camps that look identical on a homepage. Some brands are storefronts for approved products. LillyDirect and NovoCare, run by the drug makers, sell brand tirzepatide and semaglutide, sometimes at reduced cash prices. Others build their offer around compounded semaglutide or tirzepatide prepared by a compounding pharmacy. Medvi sits in the compounded camp for much of its catalog, as do several of its direct competitors, though many brands now straddle both.
This matters because compounded medication is not an FDA-approved product. It may contain the same active molecule as the brand, but it has not been through the approval process that produced the trial evidence, and the FDA has been explicit that compounded drugs do not carry the agency’s finding of safety and effectiveness. That is a fact about the product, and it belongs at the center of any fair comparison rather than in a footnote.
Why do the prices look so different?
A flat monthly figure from a compounding-focused brand and a copay figure from a brand storefront are not the same purchase. The first is a cash price for a product outside the approval framework. The second is a prescription for an approved drug, sometimes discounted by the manufacturer, sometimes routed through insurance. When a Medvi review says the price beats a competitor, the useful question is which product each price refers to.
| Brand type | Typical product | What sets the price | Main limitation |
|---|---|---|---|
| Compounding-focused telehealth | Compounded semaglutide or tirzepatide | Flat monthly cash price | Not an FDA-approved product |
| Maker storefront | Brand Wegovy, Zepbound, Mounjaro | Manufacturer self-pay or copay | Higher cash price, coverage conditions |
| Hybrid telehealth | Either, depending on eligibility | Product type and plan status | Menu shifts with supply and rules |
Is the medication itself different across brands?
Within a single product type, the active drug is the same molecule regardless of the storefront. Tirzepatide is tirzepatide. The evidence behind it comes from trials like SURMOUNT-1, which reported mean weight reduction of roughly 15 to 21 percent across doses over 72 weeks, and was echoed in SURMOUNT-CN in Chinese adults and in SURMOUNT-4, which showed that stopping treatment gave much of the loss back. A 2024 head-to-head of semaglutide and tirzepatide favored tirzepatide for weight loss. None of that evidence was generated using compounded versions, and that gap is the point.
So the meaningful difference between Medvi and a competitor is not usually the molecule. It is the product type, the prescriber relationship, and how carefully dosing is handled.
What do the reviews usually miss?
Most Medvi reviews rank brands on price and shipping speed. Both are real, but they are the least clinically important variables. What separates a responsible telehealth practice from a vending machine is whether a licensed clinician is actually prescribing and following the case, and whether dosing instructions are clear. That last point is not abstract. A poison control case series documented administration errors with compounded semaglutide, including patients drawing up several times the intended dose from multi-dose vials. A 2025 pharmacovigilance study of the FDA adverse event reporting system found a distinct signal of dosing and administration problems tied to compounded GLP-1 products.
Those errors happen at the seam between a mail-order vial and a patient left to measure a dose. A brand that treats prescribing as a real clinical relationship reduces that risk. A brand that treats it as a checkout step does not.
How should someone compare fairly?
Compare like with like. Set compounded offers against other compounded offers, and brand storefronts against other brand storefronts. Within the compounded group, weigh the flat monthly price against refill terms, whether a clinician reviews each renewal, and how dosing is explained. Physician-supervised telehealth practices publish flat monthly pricing for compounded tirzepatide, and one worked example of how to read those terms sits at formblends.com, which is one legitimate option among the field rather than a default pick.
If the goal is an approved product, LillyDirect and NovoCare are the direct routes, and a review comparing them to Medvi should say plainly that it is comparing two different categories.
Where does most of the risk actually sit?
Guidance for clinicians on compounded semaglutide stresses verifying the source pharmacy, confirming the concentration on the label, and never assuming a compounded vial is dosed like the brand pen. For a patient choosing a telehealth brand, the practical version is simple: favor a brand that names its prescriber, states the concentration clearly, and does not leave dose math to the buyer. The type 2 diabetes literature that first mapped these drugs assumed exact, supervised dosing, and that assumption does not carry over automatically to a mail-order compound.
Key takeaways
- Medvi and its rivals split into compounded sellers and approved-product storefronts, and those are different purchases.
- Compounded semaglutide and tirzepatide are not FDA-approved products.
- Within one product type the molecule is the same, so prescriber quality and dosing clarity decide value.
- Price-and-shipping reviews skip the safety variables that actually matter.
See also: Understanding the Skills in Demand Visa for Australian Immigration
Frequently asked questions
Is Medvi cheaper than the bigger GLP-1 telehealth brands?
Sometimes on the sticker, but the comparison only holds within the same product type. A flat monthly price for compounded medication is not the same purchase as a brand prescription filled through a pharmacy, so the numbers are not directly interchangeable.
Does Medvi prescribe brand Wegovy and Zepbound or compounded medication?
Telehealth brands in this space commonly offer both compounded semaglutide or tirzepatide and, where eligible, brand prescriptions. What a person gets depends on their plan, their prescriber, and current supply, so a review that names one price rarely describes the whole menu.
Are compounded GLP-1 medications FDA-approved?
No. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. They have not gone through the approval process behind the published trial evidence for the branded drugs.
What do Medvi reviews usually leave out?
Most reviews focus on price and shipping speed and skip the product type, the prescriber relationship, and dosing safety. Those are the factors that actually separate one telehealth brand from another.
How should someone compare these brands fairly?
Compare within a single product type: compounded against compounded, or brand against brand. Then weigh prescriber access, refill terms, and whether dosing is clearly supervised, not just the first month’s price.
